A Phase 3 Clinical Study for People With Relapsed and/or Refractory Multiple Myeloma

STUDY GOAL: To determine whether adding an investigational drug, MLN9708 (given orally), to the combination of lenalidomide and dexamethasone improves survival in patients with multiple myeloma whose disease is no longer responding or has not responded to previous treatment.

Learn more about this study

YOU MAY BE ELIGIBLE
TO PARTICIPATE IF YOU:

  • Have relapsed and/or refractory multiple myeloma (MM)
  • Have received 1 to 3 prior therapies for MM
  • Are 18 years of age or older
  • Meet other eligibility criteria
LEARN MORE ABOUT ELIGIBILITY CRITERIA

ABOUT MULTIPLE
MYELOMA

An overview of the condition,
its symptoms, and
whom it affects.

GO

WHAT IS A
CLINICAL STUDY?

Learn about the purpose
of clinical studies, how
they are set up, and
why they are important.

GO
We want to answer your questions about this study, but our office is closed now.
Would you like us to call you back?
1-877-674-3784 (1-877-MPI-DRUG)
Monday–Friday 9am–7pm ET